Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Shares Outstanding: 2019-2024

Historic Shares Outstanding for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $75.9 million.

  • Nurix Therapeutics' Shares Outstanding rose 14.59% to $76.9 million in Q3 2025 from the same period last year, while for Aug 2025 it was $76.9 million, marking a year-over-year increase of 14.59%. This contributed to the annual value of $75.9 million for FY2024, which is 55.73% up from last year.
  • As of FY2024, Nurix Therapeutics' Shares Outstanding stood at $75.9 million, which was up 55.73% from $48.7 million recorded in FY2023.
  • Nurix Therapeutics' Shares Outstanding's 5-year high stood at $75.9 million during FY2024, with a 5-year trough of $38.9 million in FY2020.
  • Over the past 3 years, Nurix Therapeutics' median Shares Outstanding value was $48.7 million (recorded in 2023), while the average stood at $57.3 million.
  • Data for Nurix Therapeutics' Shares Outstanding shows a peak YoY soared of 980.98% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Shares Outstanding stood at $38.9 million in 2020, then rose by 14.92% to $44.7 million in 2021, then grew by 5.62% to $47.2 million in 2022, then climbed by 3.28% to $48.7 million in 2023, then skyrocketed by 55.73% to $75.9 million in 2024.